139 related articles for article (PubMed ID: 17012888)
21. Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination.
Pérez-Breva L; Abad-Torreblanca R; Martínez-Beneito MÁ; Puig-Barberà J; Alemán-Sánchez S; Morant-Talamante N; Sastre-Cantón M; Vázquez-Moreno JA; Díez-Domingo J
Vaccine; 2017 May; 35(22):2949-2954. PubMed ID: 28438407
[TBL] [Abstract][Full Text] [Related]
22. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis.
De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH
Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695
[TBL] [Abstract][Full Text] [Related]
23. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
[TBL] [Abstract][Full Text] [Related]
24. Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.
Stoof SP; van Ravenhorst MB; van Rooijen DM; de Voer RM; van der Klis FRM; Boland GJ; Sanders EAM; Berbers GAM; Teunis PF
Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27881489
[TBL] [Abstract][Full Text] [Related]
25. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
[TBL] [Abstract][Full Text] [Related]
26. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
[TBL] [Abstract][Full Text] [Related]
27. Meningococcal C vaccines: the Canadian experience.
De Wals P
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
Pace D; Khatami A; McKenna J; Campbell D; Attard-Montalto S; Birks J; Voysey M; White C; Finn A; Macloed E; Faust SN; Kent AL; Heath PT; Borrow R; Snape MD; Pollard AJ
BMJ; 2015 Apr; 350():h1554. PubMed ID: 25832102
[TBL] [Abstract][Full Text] [Related]
29. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease.
Pollard AJ; Green C; Sadarangani M; Snape MD
Arch Dis Child; 2013 Apr; 98(4):248-51. PubMed ID: 23482919
[No Abstract] [Full Text] [Related]
30. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.
Larrauri A; Cano R; García M; Mateo Sd
Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059
[TBL] [Abstract][Full Text] [Related]
31. Meningococcal C conjugate vaccine: the experience in England and Wales.
Campbell H; Borrow R; Salisbury D; Miller E
Vaccine; 2009 Jun; 27 Suppl 2():B20-9. PubMed ID: 19477053
[TBL] [Abstract][Full Text] [Related]
32. Expanding prevention of invasive meningococcal disease.
Pelton SI; Gilmet GP
Expert Rev Vaccines; 2009 Jun; 8(6):717-27. PubMed ID: 19485753
[TBL] [Abstract][Full Text] [Related]
33. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign.
Trotter CL; Ramsay ME; Kaczmarski EB
Commun Dis Public Health; 2002 Sep; 5(3):220-5. PubMed ID: 12434692
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England.
Ramsay ME; Andrews N; Kaczmarski EB; Miller E
Lancet; 2001 Jan; 357(9251):195-6. PubMed ID: 11213098
[TBL] [Abstract][Full Text] [Related]
35. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.
Auckland C; Gray S; Borrow R; Andrews N; Goldblatt D; Ramsay M; Miller E
J Infect Dis; 2006 Dec; 194(12):1745-52. PubMed ID: 17109348
[TBL] [Abstract][Full Text] [Related]
36. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
[TBL] [Abstract][Full Text] [Related]
37. Impact of vaccination on meningococcal epidemiology.
Stefanelli P; Rezza G
Hum Vaccin Immunother; 2016 Apr; 12(4):1051-5. PubMed ID: 26512927
[TBL] [Abstract][Full Text] [Related]
38. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany.
Christensen H; Irving T; Koch J; Trotter CL; Ultsch B; Weidemann F; Wichmann O; Hellenbrand W
Vaccine; 2016 Jun; 34(29):3412-9. PubMed ID: 27109566
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
Vesikari T; Forsten A; Bianco V; Van der Wielen M; Miller JM
Pediatr Infect Dis J; 2015 Dec; 34(12):e298-307. PubMed ID: 26780033
[TBL] [Abstract][Full Text] [Related]
40. New frontiers in meningococcal vaccines.
Anderson AS; Jansen KU; Eiden J
Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
